Reports Q4 revenue $7.3B, consensus $7.33B. "2023 is an inflection point for Lilly – a chance to expand our impact on patients and growth potential as an R&D-driven biopharma company," said David A. Ricks, Lilly’s chair and CEO. "Over the course of this critical year, we hope to launch as many as four new medicines for challenging diseases, while advancing our next generation of molecules currently in Phase 3."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Pharma Earnings: Q4 Hits and Misses in a Post-COVID-19 World
- Eli Lilly says FDA approves Jaypirca
- Eli Lilly to invest $450M to expand manufacturing at Research Triangle Park
- Eli Lilly, Boehringer: FDA accepts sNDA for Jardiance for adults with CKD
- Donanemab CRL a ‘positive headline’ for Biogen’s Leqembi, says William Blair
